Literature DB >> 12814453

Evidence of an interaction between nifedipine and nafcillin in humans.

C C Lang1, S K Jamal, Z Mohamed, M R Mustafa, A M Mustafa, T C Lee.   

Abstract

AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP). However, there has not been any report to date on its possible interaction with nifedipine, an index substrate of the enzyme, CYP3A4.
METHODS: Nine healthy normotensive subjects participated in this randomized placebo-controlled two-way crossover study examining the effects of 5 days' pretreatment of nafcillin 500 mg or placebo four times daily on the pharmacokinetics of an oral dose of nifedipine 10 mg. Plasma nifedipine concentrations were measured by gas chromatography-mass spectro.
RESULTS: The area under the plasma nifedipine concentration-time curve (AUC0-alpha) in nafcillin-pretreated subjects (80.9 +/- 32.9 micro g l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4 +/- 93.2 micro g l-1 h-1) (P < 0.001). Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 +/- 42.0 l h-1 vs 56.5 +/- 32.0 l h-1) (P < 0.002).
CONCLUSIONS: The results show that nafcillin pretreatment markedly increased the clearance of nifedipine and suggest that nafcillin is a potent inducer of CYP enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814453      PMCID: PMC1884262          DOI: 10.1046/j.1365-2125.2003.01789.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

Review 1.  Human P450 metabolism of warfarin.

Authors:  L S Kaminsky; Z Y Zhang
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

2.  Subtherapeutic cyclosporine concentrations during nafcillin therapy.

Authors:  S A Veremis; M S Maddux; R Pollak; M F Mozes
Journal:  Transplantation       Date:  1987-06       Impact factor: 4.939

3.  Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin.

Authors:  A C Kind; T E Tupasi; H C Standiford; W M Kirby
Journal:  Arch Intern Med       Date:  1970-04

4.  The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.

Authors:  N Holtbecker; M F Fromm; H K Kroemer; E E Ohnhaus; H Heidemann
Journal:  Drug Metab Dispos       Date:  1996-10       Impact factor: 3.922

5.  Possible nafcillin-warfarin interaction.

Authors:  G M Heilker; J W Fowler; T H Self
Journal:  Arch Intern Med       Date:  1994-04-11

Review 6.  Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics.

Authors:  F Paradisi; G Corti; D Messeri
Journal:  Med Clin North Am       Date:  2001-01       Impact factor: 5.456

Review 7.  P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR.

Authors:  D J Waxman
Journal:  Arch Biochem Biophys       Date:  1999-09-01       Impact factor: 4.013

8.  Warfarin resistance with nafcillin therapy.

Authors:  G D Qureshi; T P Reinders; G J Somori; H J Evans
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

9.  Pharmacokinetics and metabolism of nifedipine.

Authors:  K D Raemsch; J Sommer
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

Review 10.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

View more
  8 in total

1.  Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Authors:  Sauzanne G Khalilieh; Ka Lai Yee; Rosa I Sanchez; Li Fan; Matt S Anderson; Monali Sura; Tine Laethem; Scott Rasmussen; Luc van Bortel; Griet van Lancker; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.

Authors:  Kazuto Yasuda; Aarati Ranade; Raman Venkataramanan; Stephen Strom; Jonathan Chupka; Sean Ekins; Erin Schuetz; Kenneth Bachmann
Journal:  Drug Metab Dispos       Date:  2008-05-27       Impact factor: 3.922

Review 3.  Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.

Authors:  Philip I Hair; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics.

Authors:  S K Quinney; A N Mohamed; M F Hebert; D M Haas; S Clark; J G Umans; S N Caritis; L Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

Review 5.  Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.

Authors:  Siang Fei Yeoh; Tae Jin Lee; Ka Lip Chew; Stephen Lin; Dennis Yeo; Sajita Setia
Journal:  Infect Drug Resist       Date:  2018-05-30       Impact factor: 4.003

6.  A fatal case of nafcillin-induced hepatotoxicity: a case report and the literature review.

Authors:  Mian Bilal Alam; Amin Kadoura; Magesh Sathaiah
Journal:  Case Rep Med       Date:  2012-07-11

7.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

8.  Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors.

Authors:  Yun-Ting Zhu; Zan Teng; Yi-Fan Zhang; Wei Li; Li-Xia Guo; Yun-Peng Liu; Xiu-Juan Qu; Quan-Ren Wang; Si-Yuan Mao; Xiao-Yan Chen; Da-Fang Zhong
Journal:  Drug Des Devel Ther       Date:  2020-05-20       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.